MeSH D010022 - osteopetrosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Horizon Therapeutics Public | Interferon gamma-1b | Actimmune | 1999-02-25 | $122.816 M | Q3/22-Q2/23 |
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
77%10/13
Phase 3
17%2/12
Approved: 1Overall Success rate: 13%
All Clinical Trials
No data
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use